T. Fox

758 total citations
18 papers, 567 citations indexed

About

T. Fox is a scholar working on Immunology, Rheumatology and Hematology. According to data from OpenAlex, T. Fox has authored 18 papers receiving a total of 567 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 12 papers in Rheumatology and 5 papers in Hematology. Recurrent topics in T. Fox's work include Psoriasis: Treatment and Pathogenesis (15 papers), Spondyloarthritis Studies and Treatments (10 papers) and Rheumatoid Arthritis Research and Therapies (8 papers). T. Fox is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (15 papers), Spondyloarthritis Studies and Treatments (10 papers) and Rheumatoid Arthritis Research and Therapies (8 papers). T. Fox collaborates with scholars based in Switzerland, United States and Germany. T. Fox's co-authors include Kristian Reich, Andrew Blauvelt, Brian Porter, Atul Deodhar, Xenofon Baraliakos, Luminita Pricop, Iain B. McInnes, C. Leonardi, Ayan Das Gupta and A. Widmer and has published in prestigious journals such as Annals of the Rheumatic Diseases, British Journal of Dermatology and Arthritis Research & Therapy.

In The Last Decade

T. Fox

17 papers receiving 552 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
T. Fox Switzerland	8	424	228	196	127	62	18	567
Nihal Kundakçı Türkiye	10	258 0.6×	51 0.2×	224 1.1×	20 0.2×	52 0.8×	27	459
S. D’Adamio Italy	14	348 0.8×	51 0.2×	235 1.2×	30 0.2×	88 1.4×	23	451
U. I. Yli-Kerttula Finland	10	106 0.3×	260 1.1×	37 0.2×	71 0.6×	33 0.5×	24	399
Angela Patrì Italy	9	158 0.4×	58 0.3×	162 0.8×	28 0.2×	33 0.5×	33	333
F. Lavie France	13	195 0.5×	357 1.6×	38 0.2×	123 1.0×	19 0.3×	41	511
Kara Creamer United States	5	416 1.0×	61 0.3×	232 1.2×	229 1.8×	54 0.9×	6	489
Hannah Jethwa United Kingdom	10	178 0.4×	146 0.6×	27 0.1×	60 0.5×	16 0.3×	26	401
Jeffrey M. Sobell United States	12	256 0.6×	71 0.3×	349 1.8×	36 0.3×	50 0.8×	26	524
Pascal Charef Switzerland	10	251 0.6×	48 0.2×	168 0.9×	61 0.5×	172 2.8×	11	551
K Blomqvist Finland	11	366 0.9×	189 0.8×	229 1.2×	66 0.5×	115 1.9×	21	688

Countries citing papers authored by T. Fox

Since Specialization

Citations

This map shows the geographic impact of T. Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Fox more than expected).

Fields of papers citing papers by T. Fox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Fox. The network helps show where T. Fox may publish in the future.

Co-authorship network of co-authors of T. Fox

This figure shows the co-authorship network connecting the top 25 collaborators of T. Fox. A scholar is included among the top collaborators of T. Fox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Fox. T. Fox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Deodhar, Atul, et al.. (2020). THU0397 SYMPTOMS OF PERIPHERAL ARTHRITIS ARE SIGNIFICANTLY IMPROVED IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB. Annals of the Rheumatic Diseases. 79. 434–435. 1 indexed citations

Deodhar, Atul, Iain B. McInnes, Xenofon Baraliakos, et al.. (2019). Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Research & Therapy. 21(1). 111–111. 215 indexed citations

Braun, Jürgen, Hildrun Haibel, Manouk de Hooge, et al.. (2019). Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. Arthritis Research & Therapy. 21(1). 142–142. 31 indexed citations

Braun, Joseph M., Hildrun Haibel, Manouk de Hooge, et al.. (2018). SAT0259 Low rate of spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. Annals of the Rheumatic Diseases. 77. 992–993. 3 indexed citations

Armstrong, April W., Suzanne Jarvis, Wolf‐Henning Boehncke, et al.. (2018). Patient perceptions of clear/almost clear skin in moderate‐to‐severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. Journal of the European Academy of Dermatology and Venereology. 32(12). 2200–2207. 40 indexed citations

Mease, Philip J., Iain B. McInnes, Kristian Reich, et al.. (2018). THU0325 Secukinumab demonstrates a consistent safety profile with up to 5 years treatment in patients with psoriatic arthritis and moderate to severe plaque psoriasis: updated pooled safety analyses. Annals of the Rheumatic Diseases. 77. 381–382. 3 indexed citations

McInnes, Iain B., T.K. Kvien, Luminita Pricop, et al.. (2017). AB0766 Secukinumab provides sustained remission and low disease activity related to disease activity index for psoriatic arthritis (DAPSA): 2 year results from the future 2 study. Annals of the Rheumatic Diseases. 76. 1323–1324. 1 indexed citations

Bissonnette, Robert, Thomas A. Luger, Diamant Thaçi, et al.. (2017). Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. British Journal of Dermatology. 177(4). 1033–1042. 55 indexed citations

McInnes, Iain B., Laure Gossec, Vibeke Strand, et al.. (2017). AB0765 Secukinumab provides sustained improvement in function, quality of life and fatigue over 2 years in patients who achieved disease activity index for psoriatic arthritis (DAPSA) remission. Annals of the Rheumatic Diseases. 76. 1322–1323. 1 indexed citations

10.

Lacour, J.‐P., C. Paul, S. Jazayeri, et al.. (2017). Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. Journal of the European Academy of Dermatology and Venereology. 31(5). 847–856. 49 indexed citations

11.

Wu, Jashin J., Robert B. Penfold, Paola Primatesta, et al.. (2017). The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis. Journal of the European Academy of Dermatology and Venereology. 31(7). 1168–1175. 100 indexed citations

12.

McInnes, Iain B., Kristian Reich, Peter Nash, et al.. (2017). FRI0511 Secukinumab demonstrates consistent safety over long-term exposure in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses. Annals of the Rheumatic Diseases. 76. 683–683. 5 indexed citations

13.

Deodhar, Atul, Xenofon Baraliakos, Helena Marzo‐Ortega, et al.. (2017). THU0359 Secukinumab demonstrates consistent safety over long-term exposure (up to 3 years) in patients with active ankylosing spondylitis: pooled analysis of three phase 3 trials. Annals of the Rheumatic Diseases. 76. 340–341. 5 indexed citations

14.

Lebwohl, Mark, et al.. (2017). Secukinumab Treatment of Psoriatic Arthritis and Moderate to Severe Psoriasis Relieves Anxiety/Depression Up to 52 Weeks: An Overview From Secukinumab Phase 3 Clinical Trials. Touro Scholar (Touro College). 69. 607. 2 indexed citations

15.

Maksymowych, Walter P., Ernest Choy, Yusuf Yazıcı, et al.. (2017). AB0707 Comparative effectiveness of secukinumab and golimumab in ankylosing spondylitis assessed by matching-adjusted indirect comparison using pivotal phase 3 clinical trial data. Annals of the Rheumatic Diseases. 76. 1301–1301. 2 indexed citations

16.

Paul, C., J.‐P. Lacour, A. Khemis, et al.. (2016). Évaluation de la tolérance du sécukinumab chez les patients atteints de psoriasis en plaques modéré à sévère : résultats à 2 ans. Annales de Dermatologie et de Vénéréologie. 143(12). S192–S192.

17.

Schreiber, Stefan, B E Sands, Atul Deodhar, et al.. (2016). OP0113 No Increased Incidence of Inflammatory Bowel Disease among Secukinumab-Treated Patients with Moderate To Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies. Annals of the Rheumatic Diseases. 75. 97–98. 12 indexed citations

18.

Reich, Kristian, Andrew Blauvelt, April W. Armstrong, et al.. (2016). Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. British Journal of Dermatology. 176(3). 752–758. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact